{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:41:50Z","timestamp":1777012910648,"version":"3.51.4"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008028","name":"School of Medicine and Public Health, University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Prostate specific membrane antigen (PSMA)-based radiotracers have shown promise for prostate cancer assessment. Evaluation of quantitative variability and establishment of reference standards are important for optimal clinical and research utility. This work evaluates the variability of PSMA-based [<jats:sup>18<\/jats:sup>F]DCFPyL (PyL) PET quantitative reference standards. Consecutive eligible patients with biochemically recurrent prostate cancer were recruited for study participation from August 2016-October 2017. After PyL tracer injection, whole body PET\/CT (wbPET\/CT) was obtained with subsequent whole body PET\/MR (wbPET\/MR). Two readers independently created regions of interest (ROIs) including a 40% standardized uptake value (SUV) threshold ROI of the whole right parotid gland and separate spherical ROIs in the superior, mid, and inferior gland. Additional liver (right lobe) and blood pool spherical ROIs were defined. Bland-Altman analysis, including limits of agreement (LOA), as well as interquartile range (IQR) and coefficient of variance (CoV) was used. Twelve patients with prostate cancer were recruited (mean age, 61.8 yrs; range 54\u201372 years). One patient did not have wbPET\/MR and was excluded. There was minimal inter-reader SUV<jats:sub>mean<\/jats:sub> variability (bias\u00b1LOA) for blood pool (-0.13\u00b10.42; 0.01\u00b10.41), liver (-0.55\u00b10.82; -0.22\u00b11.3), or whole parotid gland (-0.05\u00b10.31; 0.08\u00b10.24) for wbPET\/CT and wbPET\/MR, respectively. Greater inter-reader variability for the 1-cm parotid gland ROIs was present, for both wbPET\/CT and wbPET\/MR. Comparing wbPET\/CT to the subsequently acquired wbPET\/MR, blood pool had a slight decrease in SUV<jats:sub>mean<\/jats:sub>. The liver as well as parotid gland showed a slight increase in activity although the absolute bias only ranged from 0.45\u20131.28. The magnitude of inter-subject variability was higher for the parotid gland regardless of modality or reader. In conclusion, liver, blood pool, and whole parotid gland quantitation show promise as reliable reference normal organs for clinical\/research PET applications. Variability with 1-cm parotid ROIs may limit its use.<\/jats:p>","DOI":"10.1371\/journal.pone.0283830","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T17:39:00Z","timestamp":1680802740000},"page":"e0283830","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of 18F-DCFPyL PSMA PET\/CT and PET\/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8071-1771","authenticated-orcid":true,"given":"Edward M.","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minnie","family":"Kieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve Y.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"pone.0283830.ref001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"RL Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"pone.0283830.ref002","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","article-title":"Prevention and early detection of prostate cancer","volume":"15","author":"J Cuzick","year":"2014","journal-title":"Lancet Oncol"},{"key":"pone.0283830.ref003","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2431030580","article-title":"Imaging prostate cancer: a multidisciplinary perspective","volume":"243","author":"H Hricak","year":"2007","journal-title":"Radiology"},{"key":"pone.0283830.ref004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"AM H\u00f6vels","year":"2008","journal-title":"Clin Radiol"},{"key":"pone.0283830.ref005","doi-asserted-by":"crossref","first-page":"W459","DOI":"10.2214\/AJR.13.11381","article-title":"Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy","volume":"202","author":"JJ Park","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"pone.0283830.ref006","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1007\/s00330-015-4077-5","article-title":"Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results","volume":"26","author":"SY Park","year":"2016","journal-title":"Eur Radiol"},{"key":"pone.0283830.ref007","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-Based [(18)F]DCFPyL PET\/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer","volume":"18","author":"SP Rowe","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"pone.0283830.ref008","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00330-018-5682-x","article-title":"68Ga-PSMA-PET\/CT in comparison with 18 F-fluoride-PET\/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study","volume":"29","author":"E Dyrberg","year":"2019","journal-title":"Eur Radiol"},{"key":"pone.0283830.ref009","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2214\/AJR.18.20699","article-title":"Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer","volume":"213","author":"C Lawhn-Heath","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"pone.0283830.ref010","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","article-title":"Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience","volume":"41","author":"A Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref011","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"A Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"A Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref013","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00259-017-3763-8","article-title":"Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"A Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref014","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00259-015-3206-3","article-title":"Comparison of hybrid (68)Ga-PSMA PET\/MRI and (68)Ga-PSMA PET\/CT in the evaluation of lymph node and bone metastases of prostate cancer","volume":"43","author":"MT Freitag","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","article-title":"Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy","volume":"57","author":"I Rauscher","year":"2016","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref016","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of Hybrid \u2076\u2078Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy","volume":"56","author":"M Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A Phase 2\/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET\/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)","volume":"206","author":"KJ Pienta","year":"2021","journal-title":"J Urol"},{"key":"pone.0283830.ref018","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"MS Hofman","year":"2020","journal-title":"Lancet"},{"key":"pone.0283830.ref019","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.119.227793","article-title":"Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na 18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer","volume":"61","author":"SP Rowe","year":"2020","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref020","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.rcl.2021.05.008","article-title":"PET Imaging for Prostate Cancer","volume":"59","author":"B Savir-Baruch","year":"2021","journal-title":"Radiol Clin North Am"},{"key":"pone.0283830.ref021","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","article-title":"Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer","volume":"45","author":"C Schmidkonz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref022","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13550-019-0554-1","article-title":"[68 Ga]Ga-PSMA-11 PET\/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?","volume":"9","author":"J Kuten","year":"2019","journal-title":"EJNMMI Res"},{"key":"pone.0283830.ref023","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","article-title":"68Ga-PSMA PET\/CT Detects the Location and Extent of Primary Prostate Cancer","volume":"57","author":"WP Fendler","year":"2016","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref024","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2967\/jnumed.117.190314","article-title":"Ga-PSMA-11 PET\/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters","volume":"58","author":"SA Koerber","year":"2017","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2967\/jnumed.119.241174","article-title":"Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer","volume":"61","author":"LW Chiu","year":"2020","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref026","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"F Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"G Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"key":"pone.0283830.ref028","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11307-019-01376-9","article-title":"Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18 F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake","volume":"22","author":"K Sahakyan","year":"2020","journal-title":"Mol Imaging Biol"},{"issue":"Suppl 1","key":"pone.0283830.ref029","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"RL Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref030","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.118.217588","article-title":"Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET\/CT Imaging","volume":"59","author":"RA Werner","year":"2018","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref031","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"S Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0283830.ref032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"JM Bland","year":"1986","journal-title":"Lancet"},{"key":"pone.0283830.ref033","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT","volume":"59","author":"M Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"pone.0283830.ref034","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"A Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"pone.0283830.ref035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"MS Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"pone.0283830.ref036","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pros.23919","article-title":"Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer","volume":"80","author":"B Grubm\u00fcller","year":"2020","journal-title":"Prostate"},{"key":"pone.0283830.ref037","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.crad.2017.06.116","article-title":"Early 68GA-PSMA PET\/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET\/CT","volume":"72","author":"L Domachevsky","year":"2017","journal-title":"Clin Radiol"},{"key":"pone.0283830.ref038","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12149-018-1275-7","article-title":"Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET\/CT and PET\/MR scans in recurrent prostate cancer patients","volume":"32","author":"A Ringheim","year":"2018","journal-title":"Ann Nucl Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T17:39:27Z","timestamp":1680802767000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283830"}},"subtitle":[],"editor":[{"given":"Matteo","family":"Bauckneht","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0283830","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}